Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial

BACKGROUND: A randomized multicenter phase II trial was conducted to assess the sequential treatment strategy using FOLFIRI.3 and gemcitabine alternately (Arm 2) compared to gemcitabine alone (Arm 1) in patients with metastatic non pre-treated pancreatic adenocarcinoma. The primary endpoint was the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PLoS One
Hauptverfasser: Anota, Amélie, Mouillet, Guillaume, Trouilloud, Isabelle, Dupont-Gossart, Anne-Claire, Artru, Pascal, Lecomte, Thierry, Zaanan, Aziz, Gauthier, Mélanie, Fein, Francine, Dubreuil, Olivier, Paget-Bailly, Sophie, Taieb, Julien, Bonnetain, Franck
Format: Artigo
Sprache:Inglês
Veröffentlicht: Public Library of Science 2015
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4444351/
https://ncbi.nlm.nih.gov/pubmed/26010884
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0125350
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge